MI Cancer Seek™, the first and only simultaneous WES/WTS-based assay with FDA-approved CDx indications for molecular profiling of solid tumors for both adult and pediatric patients. Read more about MI Cancer Seek and view important product information:

The Precision Medicine World Conference (@PMWCintl) is currently underway! Make plans to visit Caris at booth D1135 to learn about our unprecedented comprehensive molecular profiling offerings.

Caris Life Sciences and collaborators within the Caris Precision Oncology Alliance™ will collectively present three studies at the 2025 American Society of Clinical Oncology (@ASCO) Genitourinary Cancers Symposium. #GU25 Learn more:

As we observe #WorldCancerDay, Caris Life Sciences remains dedicated to helping patients and physicians make the most informed treatment decisions. Learn how Caris testing can make a difference:

MI Cancer Seek™ is the first and only simultaneous WES/WTS-based assay with FDA-approved CDx indications for molecular profiling of solid tumors. Available for adult & pediatric (ages 1-22) patients. Discover more & view important product info:

Join us for our upcoming Genitourinary Working Group meeting. Discover new developments within the Caris Precision Oncology Alliance (POA) and learn how we're advancing molecular science to enhance research and scholarly activities in precision oncology.

Great collaboration with Amazon Web Services (@awscloud) to accelerate research and enhance patient care through efficient data processing.

Do different classes of BRAF-mutant colorectal cancer (CRC) have different molecular profiles and clinical outcomes? Hear @IbrahimSahinMD1 discuss 1730+ cases from the Caris clinicogenomic database. #GI25

How can comprehensive molecular profiling inform our understanding of immune responses in CRC? Hear Dr. @KaramAshouri discuss how data from 20k+ Caris cases and the CALGB/SWOG 80405 trial illuminates the role of FAP and SPP1 in shaping TME. #GI25

Join Caris scientific and medical leaders as they discuss how Caris Assure™ detects incidental germline variants and the importance of identifying these when present. Register Now:

Attending ASCO GI in San Francisco? Network with Caris at booth 63 and learn how we’re helping to further innovate gastrointestinal cancer research. #GI25

Caris announces a strategic collaboration with @OntadaOncology to drive next-gen therapeutic development and advance cancer care. Learn more:

Connect with Caris Life Sciences in Phoenix during the @NRGonc Winter meeting. Our experts are ready to chat at Booth 7 about our latest research, current product offerings, and what we have in store for the future of precision medicine. #NRG2025

MI Cancer Seek™ is now available. The first and only simultaneous WES/WTS-based assay with CDx indications for adult and pediatric patients. Read more about MI Cancer Seek and view important product information. #precisionmedicine

On Tuesday, January 14, Caris Life Sciences will provide an overview of our business and discuss recent corporate achievements that position the organization to further extend its leadership position in the market. #JPM2025

Malignant phyllodes tumors are rare breast cancers with limited treatment options. A study led by @DrRaniBansal & @RosenbergerMD shows how Caris molecular profiling can help identify targeted treatment opportunities. Learn more:

MI Cancer Seek™ is now available for clinical ordering. The first and only simultaneous WES/WTS-based assay with CDx indications for adult and pediatric patients. Read more about MI Cancer Seek and view important product information.

Happy New Year from everyone at Caris. We wish you a joyful 2025!

Caris Biopharma Solutions' comprehensive and integrated suite of biopharma services delivers value across your entire program life cycle—from development through launch and beyond. Discover more: